目錄:MedChemExpress LLC>>生化試劑>> Sotorasib | MCE
CAS | 2296729-00-3 | 純度 | 99.94% |
---|---|---|---|
分子量 | 560.59 | 分子式 | C??H??F?N?O? |
供貨周期 | 現(xiàn)貨 | 規(guī)格 | 5 mg |
貨號 | HY-114277 | 應用領域 | 醫(yī)療衛(wèi)生,化工,生物產(chǎn)業(yè),制藥 |
MCE 的所有產(chǎn)品僅用作科學研究或藥證申報,,我們不為任何個人用途提供產(chǎn)品和服務,。
CAS No. : 2296729-00-3
產(chǎn)品活性:Sotorasib (AMG-510) is a first-in-class, orally bioavailable, and selective KRAS G12C covalent inhibitor. Sotorasib irreversibly inhibits KRAS G12C by locking it in an inactive GDP-bound state. Sotorasib is the first KRAS G12C inhibitor in clinical development and leads to the regression of KRAS G12C tumors.
研究領域:GPCR/G Protein
作用靶點:Ras
In Vitro: In cellular assays, Sotorasib (AMG-510) covalently modifies KRAS G12C and inhibits KRAS G12C signaling as measured by phosphorylation of ERK1/2 (p-ERK) in all KRAS p.G12C-mutant cell lines.
Sotorasib (AMG-510; 1-10 μM; 72 hours) also potently impairs cellular viability in both NCI-H358 and MIA PaCa-2 with IC50≈0.006 μM and 0.009 μM, respectively. Non-KRASG12C lines are insensitive to Sotorasib (IC50>7.5 μM).
In Vivo: In preclinical tumor models, Sotorasib (AMG-510) rapidly and irreversibly binds to KRAS G12C, providing durable suppression of the mitogen-activated protein kinase (MAPK) signaling pathway. Sotorasib (orally; once daily) is capable of inducing tumor regression in mouse models of KRAS G12C cancer.
相關產(chǎn)品:Covalent Screening Library Plus | Drug Repurposing Compound Library Plus | FDA-Approved Drug Library Plus | FDA-Approved Drug Library Mini | Bioactive Compound Library Plus | GPCR/G Protein Compound Library | Kinase Inhibitor Library | FDA-Approved Drug Library | Anti-Cancer Compound Library | Drug Repurposing Compound Library | Covalent Screening Library | Ferroptosis Compound Library | Orally Active Compound Library | Chemical Probe Library | Glutamine Metabolism Compound Library | FDA Approved & Pharmacopeial Drug Library | Anti-Lung Cancer Compound Library | Anti-Pancreatic Cancer Compound Library | Anti-Blood Cancer Compound Library | Angiogenesis-Related Compound Library | Targeted Diversity Library | Anti-Liver Cancer Compound Library | Rare Diseases Drug Library | Anti-Colorectal Cancer Compound Library | FDA-Approved Anticancer Drug Library | Human Metabolite Library | Membrane Protein-targeted Compound Library | Membrane Receptor-targeted Compound Library | LC-2 | KRAS G12C inhibitor 54 | MRTX1133 | AZA1 | RBC10 | CFL-137 | Deltarasin hydrochloride | BDP9066 | CCG-100602 | KRAS inhibitor-4 | KRas G12R inhibitor 1 | MRTX0902 | KRAS G12C inhibitor 25 | Antitumor agent-60 | KRAS G12C inhibitor 30 | KRas G12C inhibitor 1 | Spiclomazine hydrochloride | GGTI-286 hydrochloride | 6H05 | AZD4625 | SOS1-IN-6 | Antineoplaston A10 | Opnurasib | K-Ras-IN-1 | BI-0474 | Diazepinomicin | K20 | BQU57 | KRAS G12D inhibitor 12 | KRas G12C inhibitor 3
熱門產(chǎn)品線:重組蛋白 | 化合物庫 | 天然產(chǎn)物 | 熒光染料 | PROTAC | 同位素標記物 | 寡核苷酸 | 抗體 | 點擊化學
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Fluorescent Dye | PROTAC | Isotope-Labeled Compounds | Oligonucleotides | Antibodies | Click Chemistry
品牌介紹:
• MCE (MedChemExpress) 擁有200 多種*僅有化合物庫,我們致力于為*科研客戶提供前沿的高品質(zhì)小分子活性化合物;
• 50,000 多種高選擇性抑制劑,、激動劑涉及各熱門信號通路及疾病領,;
• 產(chǎn)品種類涵蓋各種重組蛋白,多肽,,常用試劑盒 ,,更有 PROTAC、ADC 等特色產(chǎn)品,,廣泛應用于新藥研發(fā),、生命科學等科研項目;
• 提供虛擬篩選,,離子通道篩選,,代謝組學分析檢測分析,藥物篩選等專業(yè)技術(shù)服務,;
• 設有專業(yè)的實驗中心和嚴格的質(zhì)控,、驗證體系;
• 提供 LC/MS,、NMR,、HPLC、手性分析,、元素分析等各項質(zhì)檢報告,,確保產(chǎn)品的高純度、高品質(zhì),;
• 產(chǎn)品的生物活性多經(jīng)各國客戶實驗驗證,;
• Nature, Cell, Science 等多種頂級期刊及制藥 Patent 收錄了MCE客戶的科研成果;
• 專業(yè)團隊跟蹤最新的制藥及生命科學研究進展,,為您提供*新的活性化合物,;
• 與世界各大制藥公司及著名科研機構(gòu)建立了長期的合作,。